🚀 VC round data is live in beta, check it out!
Skye Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Skye Bioscience and similar public comparables like Marker Therapeutics, Elicera Therapeutics, Tempest Therapeutics, Jasper Therapeutics and more.
Skye Bioscience Overview
About Skye Bioscience
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Founded
2011
HQ
Employees
16
Website
Financials (LTM)
EV
$2M
Skye Bioscience Financials
Skye Bioscience reported last 12-month revenue of —.
In the same LTM period, Skye Bioscience generated — in gross profit and had net loss of ($53M).
Revenue (LTM)
Skye Bioscience P&L
In the most recent fiscal year, Skye Bioscience reported revenue of — and EBITDA of ($55M).
Skye Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($55M) | XXX | XXX | XXX |
| Net Profit | ($53M) | XXX | ($56M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Skye Bioscience Stock Performance
Skye Bioscience has current market cap of $28M, and enterprise value of $2M.
Market Cap Evolution
Skye Bioscience's stock price is $0.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $28M | 5.5% | XXX | XXX | XXX | $-1.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSkye Bioscience Valuation Multiples
Skye Bioscience trades at (0.0x) EV/EBITDA.
Skye Bioscience Financial Valuation Multiples
As of April 18, 2026, Skye Bioscience has market cap of $28M and EV of $2M.
Equity research analysts estimate Skye Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Skye Bioscience has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.0x) | XXX | XXX | XXX |
| EV/EBIT | (0.0x) | XXX | (0.0x) | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Skye Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Skye Bioscience Margins & Growth Rates
Skye Bioscience's revenue in the last fiscal year grew by —.
Skye Bioscience's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.6M for the same period.
Skye Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 118% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.6M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Skye Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Skye Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempest Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Jasper Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Skye Bioscience M&A Activity
Skye Bioscience acquired XXX companies to date.
Last acquisition by Skye Bioscience was on XXXXXXXX, XXXXX. Skye Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Skye Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSkye Bioscience Investment Activity
Skye Bioscience invested in XXX companies to date.
Skye Bioscience made its latest investment on XXXXXXXX, XXXXX. Skye Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Skye Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Skye Bioscience
| When was Skye Bioscience founded? | Skye Bioscience was founded in 2011. |
| Where is Skye Bioscience headquartered? | Skye Bioscience is headquartered in United States. |
| How many employees does Skye Bioscience have? | As of today, Skye Bioscience has over 16 employees. |
| Who is the CEO of Skye Bioscience? | Skye Bioscience's CEO is Punit Dhillon. |
| Is Skye Bioscience publicly listed? | Yes, Skye Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Skye Bioscience? | Skye Bioscience trades under SKYE ticker. |
| When did Skye Bioscience go public? | Skye Bioscience went public in 2014. |
| Who are competitors of Skye Bioscience? | Skye Bioscience main competitors are Marker Therapeutics, Elicera Therapeutics, Tempest Therapeutics, Jasper Therapeutics. |
| What is the current market cap of Skye Bioscience? | Skye Bioscience's current market cap is $28M. |
| Is Skye Bioscience profitable? | No, Skye Bioscience is not profitable. |
| What is the current net income of Skye Bioscience? | Skye Bioscience's last 12 months net income is ($53M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.